Brief: Actinium Highlights Successful Administration Of Targeted Radiotherapy Iomab-B Across Various Bmt Centers With Ease And Without Increasing Radiation Exposure Risks To Treating Nursing Staff In The Pivotal Phase 3 Sierra Trial At The 48Th Annual Oncology Nursing Society (Ons) Congress
28/04/2023 14:10
Actinium Pharmaceuticals Inc ATNM.A :
* ACTINIUM HIGHLIGHTS SUCCESSFUL ADMINISTRATION OF TARGETED
RADIOTHERAPY IOMAB-B ACROSS VARIOUS BMT CENTERS WITH EASE AND
WITHOUT INCREASING RADIATION EXPOSURE RISKS TO TREATING NURSING
STAFF IN THE PIVOTAL PHASE 3 SIERRA TRIAL AT THE 48TH ANNUAL
ONCOLOGY NURSING SOCIETY (ONS) CONGRESS
Source text for Eikon: ID:nPn2cHyf6a
Further company coverage: ATNM.A
Recent news on Actinium Pharmaceuticals
See all newsBrief: Actinium Pharmaceuticals - Receives Two Canadian Patent Allowances For Actimab-A And Iomab-Act Programs
Brief: ctinium’s Atnm-400 Shows Strong Efficacy in TNBC, Beats Therapy Resistance at SABCS
Brief: Actinium Pharmaceuticals Says ATNM-400 Shows Superior Efficacy To Xtandi In Prostate Cancer
Brief: Actinium Pharmaceuticals Announces ATNM-400 A Novel Non-PSMA Targeting First In Class Prostate Cancer Radiotherapy Leveraging Actinium-225
Brief: Actinium Pharmaceuticals Announces Supply Agreement With Eckert & Ziegler For AC-225 Radioisotope To Support Comprehensive Development Activities